Study designs for the nonclinical safety testing of new vaccine products

Journal of Pharmacological and Toxicological Methods

Volumn 66, Issue 1, 2012, Pages 1-7

  Forster, Roy ^a  

^a SOLVO BIOTECHNOLOGY   (Hungary)

Author keywords

Local tolerance; Safety pharmacology; Safety testing; Therapeutic vaccine; Toxicology; Vaccine

Indexed keywords

VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG TOLERANCE; HISTOPATHOLOGY; IMMUNE RESPONSE; NONHUMAN; PHARMACODYNAMICS; REPEATED DRUG DOSE; STUDY DESIGN; TOXICITY TESTING; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG EVALUATION, PRECLINICAL; IMMUNITY; MICE; MODELS, ANIMAL; RABBITS; RATS; RESEARCH DESIGN; RISK ASSESSMENT; TOXICITY TESTS; VACCINES;

ANIMALIA;

EID: 84864077175     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.04.003     Document Type: Article

References (26)

1. Barrow P. Developmental and reproductive toxicity testing of vaccines. Journal of Pharmacological and Toxicological Methods 2012, March-April, 65(2):58-63.
2. Brennan F.R., Dougan G. Nonclinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine 2005, 23:3210-3222.
3. Darville T., Andrews C.W., Sikes J.D., Fraley P.L., Braswell L., Rank R.G. Mouse strain-dependent chemokine regulation of the genital tract T helper cell type 1 immune response. Infection and Immunity 2001, 69:7419-7424.
4. Depla E., Van der Aa A., Livingston B.D., Crimi C., Allosery K., De Brabandere V., et al. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. Journal of Virology 2008, 82(1):435-450.
5. Dincer Z., Jones S., Haworth R. Preclinical safety assessment of a DNA vaccine using particle-mediated epidermal delivery in domestic pig, minipig and mouse. Experimental and Toxicologic Pathology 2006, 57:351-357.
6. El Mubarak H.S., Yuksel S., van Amerongen G., Mulder P.G.H., Mukhtar M.M., Osterhaus A.D.M.E., et al. Infection of cynomolgus macaques (Macaca fascicularis) and rhesus macaques (Macaca mulatta) with different wild-type measles viruses. Journal of General Virology 2007, 88:2028-2034.
7. Note for guidance on preclinical pharmacological and toxicological testing of vaccines, CPMP/SWP/465/95 1997, EMEA.
8. Guideline on adjuvants in vaccines for human use, CHMP/VEG/134716/2004 2005, EMEA.
9. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier content, EMEA/CHMP/VWP/263499/2006 2007, EMEA.
10. Guideline on repeated dose toxicity, CPMP/SWP/1042/99 Rev 1 Corr* 2010, EMEA.
11. FDA/CBER Guidance for industry, clinical considerations for therapeutic cancer vaccines, draft guidance, FDA/CBER 2009.
12. Forster R., Appelqvist T., Brown D., Cohen B., Chaloner-Larsson G., de Swart R., et al. Pulmonary delivery of measles vaccine: Non-human primate safety study. The Toxicologist 2008, 102(1). Abstract No. 2297.
13. Glueck R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 2001, 15(Suppl. 1):S42-S44.
14. Goetz K.B., Pfleiderer M., Schneider C.K. First-in-human clinical trials with vaccines-what regulators want. Nature Biotechnology 2010, 28(9):910-916.
15. Preclinical safety evaluation of biotechnology derived pharmaceuticals, ICH S6(R1), June 2011 2011, ICH.
16. Johnson A.J., Roehrig J.T. New mouse model for dengue virus vaccine testing. Journal of Virology 1999, 73(1):783-786.
17. Kennedy R.C., Shearer M.H., Hildebrand W. Nonhuman primate models to evaluate vaccine safety and immunogenicity. Vaccine 1997, 15:903-908.
18. Niewiesk S., Prince G. Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Laboratory Animals 2002, 36:357-372.
19. Offit P.A. The Cutter incident: How America's first polio vaccine led to the growing vaccine crisis 2007, Yale University Press, New Haven, USA.
20. Pascolo S. HLA class I transgenic mice: development, utilisation and improvement. Expert Opinion on Biological Therapy 2005, 5(7):919-938.
21. Sun Yuansheng, Gruber Marion, Matsumoto Mineo Overview of global regulatory toxicology requirements for vaccines and adjuvants. Journal of Pharmacological and Toxicological Methods 2012, March-April, 65(2):49-57.
22. van der Laan J.W., Forster R., Ledwith B., Gruber M., Gould S., Segal L., et al. Nonclinical testing of vaccines: Report from a workshop. Drug Information Journal 2009, 43:97-107.
23. van Amsterdam J.G., te Biesebeek J.D., van de Kuil T., van der Laan J.W., de Wildt D.J., Vleeming W. Repeated administration of whole-cell and acellular pertussis vaccines affects haemodynamics and autonomic responsiveness. Vaccine 1998, 16(17):1668-1674.
24. Watterson C., Lanevschi A., Horner J., Louden C. A Comparative analysis of acute-phase proteins as inflammatory biomarkers in preclinical toxicology studies: Implications for preclinical to clinical translation. Toxicologic Pathology 2009, 37:28-33.
25. WHO Guidelines on Nonclinical Evaluation of Vaccines 2003, WHO, Geneva, Switzerland.
26. Wolf J.J., Kaplanski C.V., Lebron J.A. Nonclinical safety assessment of vaccines and adjuvants. Vaccine adjuvants, methods in molecular biology 2010, 29-40. Humana Press, New York. G. Davies (Ed.).